Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’ episodes
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To compare efficacy of apomorphine sublingual film (APL) and levodopa inhalation powder (CVT-301) for ‘on-demand’ treatment of Parkinson's disease ‘OFF’ episodes. Patients & methods: Patient-level data from an APL pivotal study were re-weighted to match average baseline characteristics from a CVT-301 study (SPAN-PD). Placebo-adjusted treatments were compared at week 12. Results: Improvements in predose Unified Parkinson's Disease Rating Scale Part III scores were significantly larger for APL versus CVT-301 at 60 min postdose (least squares mean difference-in-difference: -8.82; p = 0.002); difference at 30 min favored APL but was not statistically significant (-4.46; p = 0.103). Total daily ‘OFF’ time reductions were significantly larger for APL versus CVT-301 (-1.31 h; p = 0.013). Conclusion: Results suggest APL treatment may lead to improved efficacy versus CVT-301.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Poewe W, Seppi K, Tanner CM et al. Parkinson disease. Nat. Rev. Dis. Primers 3, 17013 (2017).
2.
Marras C, Beck JC, Bower JH et al. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 4, 21 (2018).
3.
Pirtosek Z, Bajenaru O, Kovacs N, Milanov I, Relja M, Skorvanek M. Update on the management of Parkinson's disease for general neurologists. Parkinsons Dis. 2020, 9131474 (2020).
4.
Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72(21 Suppl. 4), S1–S136 (2009).
5.
Thanvi BR, Lo TCN. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad. Med. J. 80(946), 452–458 (2004).
6.
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448–458 (2001).
7.
Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 20(2), 190–199 (2005).
• Reports on the long-term outcomes – including dyskinesia and motor fluctuations – experienced by patients with Parkinson's disease (PD) enrolled in a randomized controlled study.
8.
Olanow C, Kieburtz K, Rascol O et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov. Disord. 28(8), 1064–1071 (2013).
9.
Chou KL, Stacy M, Simuni T et al. The spectrum of ‘off’ in Parkinson's disease: what have we learned over 40 years? Parkinsonism Relat. Disord. 51, 9–16 (2018).
10.
Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov. Disord. 20(2), 224–230 (2005).
11.
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6), 548–560 (2020).
12.
APOKYN® (apomorphine hydrochloride injection) [Prescribing information]. US WorldMeds, LLC, KY, USA (2020).
13.
Unti E, Ceravolo R, Bonuccelli U. Apomorphine hydrochloride for the treatment of Parkinson's disease. Expert Rev. Neurother. 15(7), 723–732 (2015).
14.
INBRIJA® (levodopa inhalation powder) [Prescribing information]. Acorda Therapeutics, Inc, NY, USA (2020).
15.
KYNMOBI® (apomorphine hydrochloride) sublingual film [Prescribing information]. Sunovion Pharmaceuticals Inc, MA, USA (2020).
16.
Signorovitch JE, Sikirica V, Erder MH et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940–947 (2012).
• Illustrates how matching-adjusted indirect comparison can address common limitations of indirect comparisons using examples in the published literature.
17.
Olanow CW, Factor SA, Espay AJ et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 19(2), 135–144 (2020).
•• This is the pivotal phase III study that led to the approval of apomorphine sublingual film for the treatment of ‘OFF’ episodes in patients with PD.
18.
Farbman ES, Waters CH, LeWitt PA et al. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. Parkinsonism Relat. Disord. 81, 144–150 (2020).
19.
Grosset D, Dhall R, Gurevich T et al. Long-term efficacy of inhaled levodopa in Parkinson's disease subjects with motor fluctuations: a phase 3 open-label randomized study. Neurology 90(15 Suppl.), S26.008 (2018).
20.
LeWitt PA, Hauser RA, Pahwa R et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 18(2), 145–154 (2019).
•• This is the pivotal phase III study that led to the approval of levodopa inhalation powder for the treatment of ‘OFF’ episodes in patients with PD.
21.
Hentz JG, Mehta SH, Shill HA, Driver-Dunckley E, Beach TG, Adler CH. Simplified conversion method for unified Parkinson's disease rating scale motor examinations. Mov. Disord. 30(14), 1967–1970 (2015).
22.
Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch. Neurol. 67(1), 64–70 (2010).
23.
Thach A, Sutphin J, Coulter J, Leach C, Pappert E, Mansfield C. Patient preferences for treating ‘off’ episodes in Parkinson's disease: a discrete choice experiment. Patient Prefer. Adherence 15, 1187–1196 (2021).
24.
Vizcarra JA, Sánchez-Ferro A, Maetzler W et al. The Parkinson's disease e-diary: developing a clinical and research tool for the digital age. Mov. Disord. 34(5), 676–681 (2019).
Information & Authors
Information
Published In
Pages: 285 - 295
PubMed: 35068168
Copyright
© 2022 Sunovion Pharmaceuticals. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 23 July 2021
Accepted: 1 December 2021
Published online: 24 January 2022
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’ episodes. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0178
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Jan Kassubek, Diego Santos Garcia, Wolfgang H. Jost, Lars Wojtecki, Fradique Moreira, Miguel M. Fonseca, Glynn Harrison-Jones, Isabel Pijuan, Carmen Denecke Muhr, Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson’s disease and OFF episodes: post hoc analyses of a phase III, open-label study, Therapeutic Advances in Neurological Disorders, 10.1177/17562864251343583, 18, (2025).
- Andres Ceballos-Baumann, Bedarfsmedikation als Behandlung von Off-Phasen bei Parkinson-Patienten, Nervenheilkunde, 10.1055/a-2449-1401, 44, 03, (115-125), (2025).
- Thomas Müller, Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease, Expert Opinion on Drug Metabolism & Toxicology, 10.1080/17425255.2024.2428831, 21, 3, (279-288), (2024).
- Alfonso E. Martinez-Nunez, Peter A. LeWitt, Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson’s Disease, Journal of Parkinson’s Disease, 10.3233/JPD-230055, 13, 4, (441-451), (2023).
- Sergio A. Castillo‐Torres, Andrew J. Lees, Marcelo Merello, Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience, Movement Disorders Clinical Practice, 10.1002/mdc3.13593, 10, 2, (190-208), (2022).